Acorah Software Products - Accounts Production 19.2.450 false true true 31 December 2024 1 January 2024 false 1 January 2025 31 December 2025 31 December 2025 04234256 Mr W J Hind iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 04234256 2024-12-31 04234256 2025-12-31 04234256 2025-01-01 2025-12-31 04234256 frs-core:CurrentFinancialInstruments 2025-12-31 04234256 frs-core:Non-currentFinancialInstruments 2025-12-31 04234256 frs-core:ComputerEquipment 2025-01-01 2025-12-31 04234256 frs-core:FurnitureFittings 2025-01-01 2025-12-31 04234256 frs-core:MotorVehicles 2025-01-01 2025-12-31 04234256 frs-core:PlantMachinery 2025-12-31 04234256 frs-core:PlantMachinery 2025-01-01 2025-12-31 04234256 frs-core:PlantMachinery 2024-12-31 04234256 frs-core:SharePremium 2025-12-31 04234256 frs-core:ShareCapital 2025-12-31 04234256 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 04234256 frs-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 04234256 frs-bus:FilletedAccounts 2025-01-01 2025-12-31 04234256 frs-bus:SmallEntities 2025-01-01 2025-12-31 04234256 frs-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 04234256 frs-bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 04234256 frs-bus:Director1 2025-01-01 2025-12-31 04234256 frs-countries:EnglandWales 2025-01-01 2025-12-31 04234256 2023-12-31 04234256 2024-12-31 04234256 2024-01-01 2024-12-31 04234256 frs-core:CurrentFinancialInstruments 2024-12-31 04234256 frs-core:Non-currentFinancialInstruments 2024-12-31 04234256 frs-core:SharePremium 2024-12-31 04234256 frs-core:ShareCapital 2024-12-31 04234256 frs-core:RetainedEarningsAccumulatedLosses 2024-12-31
Registered number: 04234256
Alpharmaxim Limited
Unaudited Financial Statements
For The Year Ended 31 December 2025
Sheppards Chartered Accountants
Suite 2.2 My Buro
20 Market Street
Altrincham
Cheshire
WA14 1PF
Alpharmaxim Limited
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
Alpharmaxim Limited
Balance Sheet
As At 31 December 2025
Balance Sheet
Registered number: 04234256

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 24,395 |  | 37,009
|  |  | 24,395 |  | 37,009
CURRENT ASSETS
Debtors | 5 | 439,951 |  | 507,656 |
Cash at bank and in hand |  | 445 |  | 116,280 |
|  | 440,396 |  | 623,936 |
Creditors: Amounts Falling Due Within One Year | 6 | (1,251,338 ) |  | (1,083,492 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (810,942 ) |  | (459,556 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | (786,547 ) |  | (422,547 )
Creditors: Amounts Falling Due After More Than One Year | 7 |  | (224,879 ) |  | (279,438 )
PROVISIONS FOR LIABILITIES
Deferred Taxation |  |  | (2,221 ) |  | (4,523 )
NET LIABILITIES |  |  | (1,013,647 ) |  | (706,508 )
CAPITAL AND RESERVES
Called up share capital | 8 |  | 200 |  | 200
Share premium account |  |  | 220 |  | 220
Profit and Loss Account |  |  | (1,014,067 ) |  | (706,928 )
SHAREHOLDERS' FUNDS |  |  | (1,013,647) |  | (706,508)

Page 1
Page 2
Alpharmaxim Limited
Balance Sheet (continued)
As At 31 December 2025
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Mr W J Hind Director
30th June 2026

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Alpharmaxim Limited
Notes to the Financial Statements
For The Year Ended 31 December 2025
Notes to the Financial Statements
1. General Information
Alpharmaxim Limited is a private company, limited by shares, incorporated in England & Wales, registered number 04234256 . The registered office is 1 Century Park, Pacific Road, Altrincham, Cheshire, WA14 5BJ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The company has net liabilities at the year end. The directors have since secured finance which they deem sufficient to support the company in it's day to day activities. The directors consider that the going concern basis remains appropriate.
2.3. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Motor Vehicles | 25% on reducing balance
Fixtures & Fittings | 15% on reducing balance
Computer Equipment | 33.33% on cost

2.5. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.6. Taxation
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 25 (2024: 32)
25 32
Page 3
Page 4
Alpharmaxim Limited
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025
4. Tangible Assets

| Plant & Machinery etc.
--- | ---
| £
Cost
As at 1 January 2025 | 170,958
Additions | 916
Disposals | (6,621 )
As at 31 December 2025 | 165,253
Depreciation
As at 1 January 2025 | 133,949
Provided during the period | 13,530
Disposals | (6,621 )
As at 31 December 2025 | 140,858
Net Book Value
As at 31 December 2025 | 24,395
As at 1 January 2025 | 37,009

5. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 418,702 |  | 486,007
Other debtors | 21,249 |  | 21,649
| 439,951 |  | 507,656

6. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 27,606 |  | 33,821
Bank loans and overdrafts | 431,612 |  | 151,274
Other creditors | 683,183 |  | 785,460
Taxation and social security | 108,937 |  | 112,937
| 1,251,338 |  | 1,083,492

7. Creditors: Amounts Falling Due After More Than One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Bank loans | 224,879 |  | 279,438

Page 4
Page 5
Alpharmaxim Limited
Notes to the Financial Statements (continued)
For The Year Ended 31 December 2025
8. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 200 |  | 200

Page 5